PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma

NCT00053885 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Malignant Mesothelioma

Interventions

DRUG: PTK787/ZK 222584

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]